Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

TO Goetze, RD Hofheinz, H Schmalenberg, D Strumberg, E Goekkurt, S Angermeier, T Zander, J Potenberg, HG Kopp, D Pink, Gabriele Siegler, M Schenk, F De Vita, E Maiello, T Gaiser, D Sookthai, T Brulin, C Pauligk, N Homann, SE Al-Batran

Research output: Contribution to journalAbstract (Journal)peer-review

2 Citations (Web of Science)
Original languageEnglish
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume40
Issue number16
Publication statusPublished - 2022

Cite this